Quick Answer
Monopar Therapeutics reported Cash and Equivalents of $61.83 million for fiscal year 2025.
Monopar Therapeutics Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $61.83M | +35.0% |
| 2024 | $45.82M | +530.6% |
| 2023 | $7.27M | -11.2% |
| 2022 | $8.19M | -59.7% |
| 2021 | $20.30M | +21.3% |
| 2020 | $16.74M | +26.7% |
| 2019 | $13.21M | +91.7% |
| 2018 | $6.89M | -23.3% |
| 2017 | $8.98M | +333.4% |
| 2016 | $2.07M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $127.68M | +2020.9% | +223.2% |
| June 30, 2025 | $39.50M | +545.5% | -0.5% |
| March 31, 2025 | $39.71M | +408.6% | -13.3% |
| December 31, 2024 | $45.82M | +530.6% | +661.1% |
| September 30, 2024 | $6.02M | +9.2% | -1.6% |
| June 30, 2024 | $6.12M | -15.2% | -21.6% |
| March 31, 2024 | $7.81M | +36.4% | +7.5% |
| December 31, 2023 | $7.27M | -11.2% | +31.7% |
- Monopar Therapeutics showed an increase of +35.0% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2016–2025 period, Monopar Therapeutics’s cash and equivalents has grown by 2883.4% (from $2.07 million to $61.83 million).
- The most recent figure is from Monopar Therapeutics’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 27, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: